Pathos AI Signs Multi-Year Deals With BMS and Tempus, Including $55M License
Pathos AI announced collaborations with Bristol Myers Squibb and Tempus AI, including a five-year, $55 million Tempus data license. BMS will lead a Series E financing and receive three-year exclusive rights to apply Pathos Foundry in neuroscience.